BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164]
URL: https://www.wjgnet.com/1948-5182/full/v13/i23/3164.htm
Number Citing Articles
1
Brian I. Carr, Srikanth Nagalla. Hepatocellular Carcinoma2009; : 527 doi: 10.1007/978-1-60327-376-3_20
2
Marcello Maida, Giuseppe Cabibbo, Giuseppe Brancatelli, Chiara Genco, Nicola Alessi, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà. Assessment of treatment response in hepatocellular carcinoma: a review of the literatureFuture Oncology 2013; 9(6): 845 doi: 10.2217/fon.13.33
3
Jia Liu, Thomas Mittendorf, J.-Matthias von der Schulenburg. A Structured Review and Guide Through Studies on Health-Related Quality of Life in Kidney Cancer, Hepatocellular Carcinoma, and LeukemiaCancer Investigation 2010; 28(3): 312 doi: 10.3109/07357900903287022
4
M Caraglia, G Giuberti, M Marra, R Addeo, L Montella, M Murolo, P Sperlongano, B Vincenzi, S Naviglio, S Del Prete, A Abbruzzese, P Stiuso. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LARCell Death & Disease 2011; 2(4): e150 doi: 10.1038/cddis.2011.34
5
Claudia Pivonello, Maria Cristina De Martino, Mariarosaria Negri, Gaia Cuomo, Federica Cariati, Francesco Izzo, Annamaria Colao, Rosario Pivonello. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targetsInfectious Agents and Cancer 2014; 9(1) doi: 10.1186/1750-9378-9-27
6
Chiun Hsu, Ying-Chun Shen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial designContemporary Clinical Trials 2010; 31(1): 55 doi: 10.1016/j.cct.2009.08.002
7
Adam C. Yopp, William R. Jarnagin. Randomized Clinical Trials in Hepatocellular CarcinomaSurgical Oncology Clinics of North America 2010; 19(1): 151 doi: 10.1016/j.soc.2009.09.012
8
Brian I. Carr, Srikanth Nagalla, Ravit Geva. Hepatocellular Carcinoma2016; : 489 doi: 10.1007/978-3-319-34214-6_33
9
Maximilian Schöniger-Hekele, Joachim Kettenbach, Markus Peck-Radosavljevic, Christian Müller. Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled studyJournal of Experimental & Clinical Cancer Research 2009; 28(1) doi: 10.1186/1756-9966-28-142
10
Timothy R. Morgan. Clinical Cancer PreventionRecent Results in Cancer Research 2010; 188: 85 doi: 10.1007/978-3-642-10858-7_7
11
YAO LIU, LI JIANG, YI MU. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatmentOncology Letters 2013; 6(3): 821 doi: 10.3892/ol.2013.1435
12
Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and TherapyMolecules 2020; 25(17): 4012 doi: 10.3390/molecules25174012
13
Ioulia Evangelou, Constantina Petraki, Pavlos Msaouel, Andreas Scorilas, Eleni Sdrolia, Georgia Padazi, Vassilios Koborozos, Michael Koutsilieris. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancerEuropean Journal of Clinical Investigation 2012; 42(7): 777 doi: 10.1111/j.1365-2362.2012.02648.x
14
Hanna K. Sanoff, Richard Kim, Anastasia Ivanova, Angela Alistar, Autumn J. McRee, Bert H. O’Neil. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinomaInvestigational New Drugs 2015; 33(2): 505 doi: 10.1007/s10637-015-0209-7
15
Xi Chen, Xiao-Yu Zhang, Yang Shen, Li-Li Fan, Mu-Lan Ren, Yong-Ping Wu. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude miceOncotarget 2016; 7(50): 83451 doi: 10.18632/oncotarget.13120
16
S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola, C. Ciafardini, M. Colombo, M. Peracchi. Chromogranin A levels in chronic liver disease and hepatocellular carcinomaDigestive and Liver Disease 2009; 41(1): 31 doi: 10.1016/j.dld.2008.05.002
17
Li Su, WenFang Xu. Peptidomimetics and metalloprotease inhibitors as anticancer drugsScience in China Series B: Chemistry 2009; 52(5): 535 doi: 10.1007/s11426-009-0040-0
18
Nuh N. Rahbari, Arianeb Mehrabi, Nathan M. Mollberg, Sascha A. Müller, Moritz Koch, Markus W. Büchler, Jürgen Weitz. Hepatocellular CarcinomaAnnals of Surgery 2011; 253(3): 453 doi: 10.1097/SLA.0b013e31820d944f
19
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the LiteratureInternational Journal of Molecular Sciences 2019; 20(19): 4811 doi: 10.3390/ijms20194811
20
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Ioana Anca Badarau, Andreea-Elena Scheau, Mircea Tampa, Simona Roxana Georgescu, Andreea Cristiana Didilescu, Cristian Scheau, Constantin Caruntu, Maria Beatrice Morelli. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular CarcinomaAnalytical Cellular Pathology 2021; 2021: 1 doi: 10.1155/2021/1840069
21
Hao-Wen Sim, Jennifer Knox, Laura A. Dawson. An Update on Randomized Clinical Trials in Hepatocellular CarcinomaSurgical Oncology Clinics of North America 2017; 26(4): 647 doi: 10.1016/j.soc.2017.05.006
22
Kerstin Wohlleber, Patrick Heger, Pascal Probst, Christoph Engel, Markus K. Diener, André L. Mihaljevic. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategiesQuality of Life Research 2021; 30(9): 2429 doi: 10.1007/s11136-021-02810-8
23
Omar Abdel-Rahman, Angela Lamarca, Juan W Valle, Richard A Hubner. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerationsEndocrine-Related Cancer 2014; 21(6): R485 doi: 10.1530/ERC-14-0389
24
Jean-Claude Barbare, Olivier Bouché, Franck Bonnetain, Laetitia Dahan, Catherine Lombard-Bohas, Roger Faroux, Jean-Luc Raoul, Stéphane Cattan, Alain Lemoine, Jean-Frédéric Blanc, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Sophie Cazorla, Dany Gargot, Thierry Thevenot, Emmanuel Diaz, Anne Bastie, Thomas Aparicio, Laurent Bedenne. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled studyEuropean Journal of Cancer 2009; 45(10): 1788 doi: 10.1016/j.ejca.2009.02.018
25
Maria Cristina De Martino, Leo J. Hofland, Steven W.J. Lamberts. Neuroendocrinology - Pathological Situations and DiseasesProgress in Brain Research 2010; 182: 255 doi: 10.1016/S0079-6123(10)82011-4
26
Malgorzata Trofimiuk-Müldner, Alicja Hubalewska-Dydejczyk. Somatostatin Analogues2015; : 135 doi: 10.1002/9781119031659.ch12
27
Monica Marra, Ignazio M Sordelli, Angela Lombardi, Monica Lamberti, Luciano Tarantino, Aldo Giudice, Paola Stiuso, Alberto Abbruzzese, Rossella Sperlongano, Marina Accardo, Massimo Agresti, Michele Caraglia, Pasquale Sperlongano. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overviewJournal of Translational Medicine 2011; 9(1) doi: 10.1186/1479-5876-9-171
28
Xi-Qing Ji, Xin-Jian Ruan, Hong Chen, Gang Chen, Shi-Yong Li, Bo Yu. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trialsMedical Science Monitor 2011; 17(8): RA169 doi: 10.12659/MSM.881892
29
Tian-Kang Guo, Xiang-Yong Hao, Bin Ma, Ke-Hu Yang, Yi-Ping Li, Hong-Ling Li, Yuan-Hui Gu, Hui Cai, Ya-Li Liu, Yuan Li, Wei-Peng Zhan. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trialsJournal of Cancer Research and Clinical Oncology 2009; 135(12): 1685 doi: 10.1007/s00432-009-0615-3
30
Marialuisa Appetecchia, Roberto Baldelli. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectivesJournal of Experimental & Clinical Cancer Research 2010; 29(1) doi: 10.1186/1756-9966-29-19
31
Chapter 4: Chemotherapy and radiotherapyHepatology Research 2010; 40: 74 doi: 10.1111/j.1872-034X.2010.00657.x
32
Dimitrios N. Samonakis, George Notas, Nikolaos Christodoulakis, Elias A. Kouroumalis. Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma: A Message Not Well TakenDigestive Diseases and Sciences 2008; 53(9): 2359 doi: 10.1007/s10620-007-0175-9
33
Giuseppe Cabibbo, Marco Enea, Massimo Attanasio, Jordi Bruix, Antonio Craxì, Calogero Cammà. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinomaHepatology 2010; 51(4): 1274 doi: 10.1002/hep.23485
34
Pavlos Msaouel, Evanthia Galanis, Michael Koutsilieris. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biologyExpert Opinion on Investigational Drugs 2009; 18(9): 1297 doi: 10.1517/13543780903176399
35
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targetsBMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3911-3
36
G. Treiber, T. Wex, P. Malfertheiner. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancerJournal of Cancer Research and Clinical Oncology 2009; 135(2): 271 doi: 10.1007/s00432-008-0443-x
37
Wei-Dong Jia, Ge-Liang Xu, Wei Wang, Zhi-Hua Wang, Jian-Sheng Li, Jin-Liang Ma, Wei-Hua Ren, Yong-Sheng Ge, Ji-Hai Yu, Wen-Bin Liu. A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in MiceThe Tohoku Journal of Experimental Medicine 2009; 218(2): 155 doi: 10.1620/tjem.218.155
38
Simone Krebs, Mark Dunphy. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set2017; : 285 doi: 10.1016/B978-0-323-34062-5.00017-0